TeleCareSpot Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6/10
Best for: compounded semaglutide at $299/month
TeleCareSpot's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
One rate covers every GLP-1 dose: $299/month for compounded semaglutide, $399/month for compounded tirzepatide, all-inclusive, with oral tirzepatide and phentermine also stocked. US-licensed physicians read the intake and write the script. An optional DNA-calibrated route pitches dose against metabolism. LegitScript certification is verifiable, HIPAA compliance is claimed, delivery is free and you can quit whenever. Availability stops at 47 states plus DC, leaving out Alaska, Mississippi and New Jersey. Compounded drugs lack FDA approval and the pharmacy is never named.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to TeleCareSpot
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
TeleCareSpot at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Oral tirzepatide
- Starting price
- $299/mo ($299/month flat, all doses; everything included, no hidden fees. Separate consult fee credited toward the package if...)
- What's included
- Medication · Consult · Shipping
- Availability
- 48 states
- FDA status
- No FDA warning letter on record
How TeleCareSpot scores
Six columns, each one computed from something TeleCareSpot has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
2.1/10$399/month is 49% above the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
3.0/10On the seller's own pages, no price appears until the medical intake is finished.
Trust & Safety15%
6.0/10does not name a dispensing pharmacy; withholds price until after the intake; publishes its state list. Our verification confidence is high.
Accessibility10%
9.7/10Publishes coverage in 48 of 50 states.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on TeleCareSpot
Last checked June 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with TeleCareSpot involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1TeleCareSpot does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3TeleCareSpot does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $299, tirzepatide $399. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 48 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
TeleCareSpot support, as documented
GLP-1 medications TeleCareSpot offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
$299/month flat, all doses; everything included, no hidden fees. Separate consult fee credited toward the package if approved.
$399/month flat, all doses; everything included. Oral tirzepatide and phentermine also offered (price at intake).
Check the price yourself before you pay
Every figure here was read off TeleCareSpot's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- The monthly figure covers medication, consult, shipping
- Coverage is published for 48 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Semaglutide at $299 a month, 58% above the $189 register median for the same drug and form
- Tirzepatide at $399 a month, 49% above the $267 register median for the same drug and form
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What TeleCareSpot charges
TeleCareSpot lists $299/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- Compounded semaglutide — $299/month
- Compounded tirzepatide — $399/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Direct Meds dispenses semaglutide and tirzepatide from $249/month, which makes it the honest comparison to run before committing here.
What TeleCareSpot dispenses
TeleCareSpot prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at TeleCareSpot at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- injections are the thing keeping you from starting
- you need access regardless of where you live
Our read
TeleCareSpot costs more than the middle of this market, and the oral option is the clearest thing that premium buys. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less. MangoRx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
TeleCareSpot's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay TeleCareSpot
Starting at $299/month. Check today's price, then book the free consultation.
Where TeleCareSpot is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this TeleCareSpot review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See TeleCareSpot's current pricing
Plans start at $299/month. The free consultation is where you learn whether you qualify, and what it costs today.